Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
Zijun Y. Xu‐Monette(Duke University), Ken H. Young(Duke Medical Center), Yu Chuan Tai(Roche (Switzerland)), Michael Møller(Hospital South West Jutland), Karen Dybkær(Aalborg University Hospital), Govind Bhagat(Columbia University Irving Medical Center), Maurilio Ponzoni(San Raffaele University of Rome), Eric D. Hsi(Mayo Clinic), Ronald S. Go(Mayo Clinic), J. Han van Krieken(Radboud University Nijmegen), Qin Huang(City Of Hope National Medical Center), Attilio Orazi(Texas Tech University), Wei Xu(Jiangsu Province Hospital), Wei‐Min Liu(Roche (Switzerland)), Alexandar Tzankov(University of Basel), Carlo Visco(University of Verona), Weiyun Z. Ai(University of California, San Francisco), Kristy L. Richards(University of North Carolina at Chapel Hill), April Chiu(Mayo Clinic), Lynne V. Abruzzo(The University of Texas MD Anderson Cancer Center), Roberto N. Miranda(The University of Texas MD Anderson Cancer Center), Youli Zu(Methodist Hospital), Brad S. Kahl(UW Health University Hospital), Miguel Á. Piris(Hospital Universitario Fundación Jiménez Díaz), Santiago Montes‐Moreno(Universidad de Cantabria), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Lin Wu(Materials Systems (United States)), Jooryung Huh(Asan Medical Center), Yong Li(Baylor College of Medicine), Fan Zhou(Southwest Washington Medical Center), Jianyong Li(Jiangsu Province Hospital), Xiaoying Zhao(Second Affiliated Hospital of Zhejiang University), William W.L. Choi(Chinese University of Hong Kong), L. Jeffrey Medeiros(Delaware Division of Libraries), X. Frank Zhao(University of Maryland, Baltimore), Jane N. Winter(Northwestern University)
Cited by 390
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k